08:23 AM EDT, 08/18/2025 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) said Monday it initiated a rolling submission of a biologics license application for its DTX401 AAV gene therapy as treatment for glycogen storage disease Type Ia with the US Food and Drug Administration.

The company said it aims to complete the full application, including submission of the chemistry, manufacturing and controls module, in the fourth quarter.